The IMF Says Newly Published Study Confirms Survival Advantage with Revlimid® and Further Advantages With Continuous Use in Newly Diagnosed Multiple Myeloma Patients Not Eligible for Transplant

Source: International Myeloma Foundation - Category: Hematology Source Type: news